MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials
MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials
复制标题
DOI：
10.1111/maq.12548
复制
发表时间：
2020-05-18
影响因子：
2.2
通讯作者：
Hendy, Katherine
中科院分区：
文献类型：
--
作者：
Hendy, Katherine
非营利组织致力于开发+/- 3,4-亚甲二氧基甲基苯丙胺 (MDMA)（更广为人知的街头毒品摇头丸）作为处方药，这为检验药物作为流体物体在新信息和物质环境中转变的最新理论提供了机会。本文根据人种学研究，质疑 MDMA 研究人员对 MDMA 和街头毒品摇头丸的区别。虽然研究人员认为纯 MDMA 与摇头丸不同，但本文认为两者之间的区别不在于物质上的区别，而在于必须通过试验产生的安全性区别。本文通过临床文件的相互关联的工作来跟踪安全性的产生，这些文件管理允许哪些身体吸收药物以及哪些身体事件算作效果。 MDMA 的安全性来自于通过这些记录实践对关系的谨慎管理。
Nonprofit efforts to develop +/- 3,4-methylenedioxymethamphetamine (MDMA)-better known as the street drug Ecstasy-as a prescription pharmaceutical provide the opportunity to examine recent theorizations of pharmaceuticals as fluid objects transformed in new informational and material environments. Drawing from ethnographic research, this article interrogates MDMA researchers' own distinction between MDMA and the street drug Ecstasy. While researchers maintain that pure MDMA is distinct from Ecstasy, this article argues that the difference between the two hangs not on a distinction in substance, but on a distinction in safety that must be produced through the trial. This article tracks the production of safety through the inter-connected work of clinical documents, which manage both which bodies are allowed to absorb the drug and which bodily events count as effects. MDMA's safety emerges from the careful management of relations through these documentary practices.